Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Durect Eyes Phase III In Alcoholic Hepatitis Despite Phase IIb Miss

Nov 08 2023

• By Joseph Haas

Liver — Durect hopes to move into Phase III in alcoholic hepatitis despite Phase IIb miss

Related Content

Deal Watch: Merck's Busy Stretch Includes Collaborations With Dewpoint, Zymeworks

Jul 13 2020

Italy’s Alfasigma Comes Calling After Intercept’s Cruel Summer

Sep 26 2023

Related Companies

DURECT Corporation

Intercept Pharmaceuticals, Inc.

Evive Biotech

Aldeyra Therapeutics, Inc.

Surrozen Inc.

Gilead Sciences, Inc.

Additional Topics

Clinical Trials Business Strategies Drug Approval Standards Research & Development Liver & Hepatic BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window